Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation

- 1 Pranay Bharadwaj¹* (ORCID: 0000-0003-3768-3557), Sweta Shrestha¹* (ORCID: 0000-0002-5065-
- 2 3961), Tamas Pongracz²* (ORCID: 0000-0002-8089-4352), Catalano Concetta^{3,4}* (ORCID: <u>0000-</u>
- 3 0001-7858-1544), Shilpee Sharma³(ORCID: 0000-0003-4645-9442), Alain Le Moine⁴ (ORCID: 0000-
- 4 <u>0001-7575-9255</u>), Noortje de Haan^{2,\$} (ORCID: 0000-0001-7026-6750), Naoka Murakami⁵ (ORCID:
- 5 0000-0001-8168-5811), Leonardo V. Riella^{6,7} (ORCID: 0000-0002-7636-3196), Vanda Holovska⁸
- 6 (ORCID: 0000-0002-2204-558X), Manfred Wuhrer² (ORCID: 0000-0002-0814-4995), Arnaud
- 7 Marchant³ (ORCID: 0000-0003-0578-0467), Margaret E. Ackerman^{1,9,#} (ORCID: 0000-0002-4253-
- 8 3476)
- 9
- 10
- ¹¹ ¹Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth
- 12 College, Hanover, NH, USA
- ²Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The
 Netherlands
- ¹⁵ ³Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium
- ⁴Department of Nephrology, Dialysis and Renal transplantation, Hôpital Erasme, Université libre de
- 17 Bruxelles, Bruxelles, Belgium
- ⁵Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 19 ⁶Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 20 ⁷Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital,
- 21 Boston, MA, USA
- 22 ⁸HLA laboratory, Laboratoire Hospitalier Universitaire de Bruxelles (LHUB), Hôpital Erasme ULB,
- 23 Brussels, Belgium
- 24 ⁹Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
- 25 *Share first authorship
- 26 ^{\$}Current affiliation: Department of Cellular and Molecular Medicine, Copenhagen Center for
- 27 Glycomics, University of Copenhagen, Copenhagen, Denmark
- 28 [#]Corresponding Author
- 29 Margaret E. Ackerman
- 30 14 Engineering Drive
- 31 Hanover, NH 03755
- 32 margaret.e.ackerman@dartmouth.edu
- 33 (ph) 603 646 9922
- 34 (fax) 603 646 3856

35 Summary

36 Antibody-mediated rejection (AMR) is the leading cause of graft failure. While donor-specific 37 antibodies (DSA) are associated with a higher risk of AMR, not all patients with DSA develop 38 rejection suggesting that the characteristics of alloantibodies that determine their pathogenicity 39 remain undefined. Using human leukocyte antigen (HLA)-A2-specific antibodies as a model, we 40 applied systems serology tools to investigate gualitative features of immunoglobulin G (IgG) 41 alloantibodies including Fc-glycosylation patterns and FcyR binding properties. The levels of 42 afucosylation of anti-A2 antibodies were elevated in all seropositive patients and were significantly 43 higher in AMR patients, suggesting potential cytotoxicity via FcyRIII-mediated mechanisms. 44 Afucosylation of both glycoengineered monoclonal and naturally glycovariant polyclonal serum IgG 45 specific to HLA-A2 exhibited potentiated binding to, slower dissociation from, and enhanced 46 signaling through FcyRIII, a receptor widely expressed on innate effector cells. Collectively, these 47 results suggest that afucosylated DSA may be a biomarker of AMR and could contribute to its 48 pathogenesis.

49 Keywords

⁵⁰ IgG, effector function; donor-specific antibody; glycosylation; ADCC; antibody-mediated rejection;

- 51 afucosylation; transplantation
- 52

53 Abstract word count: 150

54 **Character count:**

55 Introduction

56 Antibody-mediated rejection (AMR), encompassing allograft rejection caused primarily by 57 antibodies directed against donor-specific human leukocyte antigen (HLA) molecules, is the leading 58 cause of solid organ transplant rejection and long-term graft loss (1-5). AMR is characterized by 59 histological manifestations of endothelial cell injury, mononuclear cell infiltration and complementdependent tissue damage. Additionally, the presence of circulating donor-specific antibodies (DSA) 60 61 poses challenges for transplant recipients by limiting access to available organs, prolonging wait 62 time, and in some cases, excluding the candidates from a possible transplantation altogether (6-8). 63 Solid phase assays using purified HLA antigens (Luminex® single bead antigen assays) have 64 significantly improved stratification and categorization of transplant candidates, because they can 65 detect very low levels of DSAs due to their high sensitivity. While this technique has been used to 66 update organ allocation and desensitization protocols, it has led to minimal benefits to improvement 67 in rejection treatment, as the presence and levels of DSA are not a reliable predictor of transplant 68 outcome (9-13). While graft survival is clearly poorer for individuals sensitized against donor organ 69 antigens (1, 2, 14-17), several studies have shown that not all DSAs carry the same risk of allograft 70 rejection, as they have been associated with a wide spectrum of effects ranging from a complete 71 absence of graft injury to the most severe form of AMR (18). Similarly, appearance of de novo DSA 72 implies the risk of graft deterioration but provides little to no information on their actual pathogenic 73 activities (3, 19-22).

74

75 Collectively, these observations point to the importance of factors other than the magnitude of the 76 DSA response as important drivers of pathology. Clinical practice is challenged by the lack of strong 77 relationships between antibody characteristics and patient outcomes. Given the profound 78 disproportion between available organs and the number of patients waiting for a transplant, the US 79 Food and Drug Administration (FDA) recently identified AMR and desensitization as two important 80 areas in transplantation for which no drugs have been specifically approved (1, 2, 23-25). Techniques 81 which better define DSAs properties may be required to first advance mechanistic understanding of 82 AMR and secondly to improve transplant recipient outcomes.

83

84 To this end, the antibody effector functions that may be responsible for AMR are influenced not 85 solely by titer, but by affinity, antigen availability and epitope, and antibody isotype, subclass, and 86 glycosylation (12, 26-31). In other disease settings, systematic tools for surveillance of this spectrum 87 of serum antibody features and their associated effector functions have identified reliable 88 associations and begun to support robust predictions of disease outcomes (32-39). While prior 89 research on the role of antibodies in transplant rejection was predominantly focused on estimation 90 and retrospective correlation of titer to better predict transplant outcomes (16, 17, 40-42), recent 91 studies have begun to interrogate other important factors governing antibody functionality, such as 92 subclass distribution and complement fixing ability (12, 27, 28, 43-51), and the evolution of these 93 features with the progression of disease (13, 48, 52-57).

94

95 Here, we report on the development and application of novel assays to characterize phenotypic and 96 functional aspects of HLA-specific antibodies. Among a group of individuals with antibodies against 97 HLA-A2, we observe altered Fc glycosylation profiles as compared to total serum IgG - most 98 notably, enrichment of afucosylated IgG1 antibodies, which are widely associated with potentiated 99 antibody-dependent cellular cytotoxicity (ADCC) (58-63). For both glycoengineered monoclonal as 100 well as polyclonal, human serum-derived HLA-A2-specific antibodies, binding to, and signaling via 101 FcyRIIIa, the receptor expressed on NK and other innate immune cells and responsible for mediating 102 ADCC, were negatively associated with fucosylation. Collectively, this work establishes the potential 103 importance of DSA Fc glycosylation in influencing the ADCC activity of DSA, and in turn, their ability 104 to contribute to graft rejection.

105

106 Methods

107 Sample selection and study cohort

108 Clinical sample collection and analysis were approved by the Ethics Review Board of the Hôpital 109 Erasme, Brussels, Belgium. Written informed consent was obtained from study participants. Clinical 110 characteristics were collected from the patient's electronic medical records (Transkid-RedCap). 111 (Supplemental Tables 1, 2). Patients with detectable anti-HLA-A2 alloantibodies were included in

112 the study. Patients without detectable anti-A2 antibodies were included as controls. Anti-HLA-A2 113 antibodies were detected using clinical Luminex® single antigen bead assay according to the 114 manufacturer's instructions (Immucor[®] Lifecodes). Following incubation with serum, Mean 115 Fluorescence Intensity (MFI) of HLA antigen-coated beads was measured with a fluoroanalyser using 116 xPonent software for data acquisition and Match It! Software (Immucor®Lifecodes) for data analysis. 117 Positivity thresholds were defined according to the manufacturer's instructions. For individuals with 118 renal transplant, AMR was diagnosed based on clinical parameters (serum creatinine and proteinuria) 119 and renal transplant biopsy, when contributive. AMR histological characteristics were glomerulitis, 120 peritubular capillaritis, microvascular inflammation and C4d immunostaining positivity.

121

122 Cloning and expression of recombinant HLA-A2 mAbs

123 Variable domain gene sequences of the heavy and the light chain (V_H and V_L) of mouse HLA-A2 124 hybridoma cells (ATCC, HB-82 BB7.2) were defined to support recombinant production of a panel 125 of human subclass-switched chimeric antibodies. Briefly, mRNA was isolated from hybridoma cells 126 using the RNeasy kit (Qiagen, Cat No./ID: 74104), and cDNA generated using the VRSO cDNA kit 127 (ThermoFisher, AB1453A). This cDNA was then amplified using degenerate primers (65) to 128 selectively amplify V_H and V_L regions, which were sequenced and cross-referenced and annotated 129 using BLAST and IMGT-based tools. Verified V_H and V_L sequences were used to design gene blocks 130 (Twist Biosciences) that contained murine V_H, V_L, C_L and C_H1 domains paired with human hinge and 131 C_{H2} and C_{H3} Fc domains for each IgG subtype (Supplemental Table 3). These gene blocks were 132 cloned by overlap extension into the pCMV expression plasmid.

133 Chimeric antibodies were transiently expressed via heavy and light chain plasmid co-transfection in 134 HEK-expi293 cells, and purified using Protein A (IgG1, IgG2, and IgG4) or Protein G (IgG3) 135 chromatography as previously reported (66, 67). Afucosylated IgG1 and IgG3 were produced by 136 adding 0.15 mM of 2-fluorofucose (2FF) substrate in the growth medium, as described (67).

137 IgG subclass and titer measurements

A custom multiplex assay was performed as previously described (68, 69) in order to define the total
levels and subclass profiles of HLA-A2-, HLA-A1- (NIH Tetramer Facility, HLA-A*02:01 complexed

140 with either CLGGLLTMV peptide from Epstein Bar Virus membrane protein or GLCTLVAML peptide 141 from Epstein Bar Virus mRNA export factor ICP27, HLA-A*01:01 complexed with VTEHDTLLY from 142 cytomegalovirus pp50), and HSV-gD- (Immune Technology IT-005-055p) specific antibodies. Briefly, 143 antigen-coupled microspheres were diluted in Assay Buffer (PBS + 0.1% BSA + 0.05% Tween20), 144 and mAb or serum, followed by washing and detection with R-phycoerythrin (PE)-conjugated anti-145 Human IgG (Southern Biotech #9040-09), anti-mouse IgG (Biolegend #405307) or anti-human IgG1 146 (#9054-09), IgG2 (Southern Biotech #9070-09), IgG3 (Southern Biotech # 1100-09) and IgG4 147 (Southern Biotech #9200-09), respectively. Median fluorescent intensities (MFI) were acquired on a 148 FlexMap 3D (Luminex).

149 Affinity purification of HLA-A2-specific antibodies

150 HLA-A2-specific antibodies were purified from human sera using magnetic, antigen-conjugated 151 beads (Supplemental Table 4). Magnetic streptavidin coated beads (NEB, S1420S) were incubated 152 with biotinylated HLA-A2. Briefly, 50 µL streptavidin beads were washed with wash buffer (0.5M 153 NaCl, 20mM Tris-HCl (pH 7.5), 1mM EDTA) followed by incubation with 20 µg biotinylated HLA-A2 154 for 2 hours at room temperature or overnight at 4°C. After washing five times, beads were blocked 155 using 200 µL heat inactivated FBS for 2 hours. For purification, 150 µL of beads were co-incubated 156 with 50 µL of sera for 3 hours on a rotational mixer, followed by three washes using PBS-TBN (PBS-157 1X, 0.1% BSA, 0.02% Tween 20, 0.05% sodium azide, pH 7.4). HLA-A2-specific antibodies were 158 eluted by resuspending beads in 50 µL of 1% formic acid (pH 2.9) and incubating on a rotational 159 mixer for 10 min at room temperature. Supernatant was withdrawn and 20 µL of 0.5 M sodium 160 phosphate dibasic was added to each tube to neutralize the pH. The resulting eluate was split into 161 two parts and used for LC-MS-based IgG Fc glycosylation analysis as well as for enrichment 162 confirmation analysis, as described above.

163 Sample preparation for LC-MS based Fc glycosylation analysis

Affinity purified HLA-A2-specific IgG were subjected to tryptic digestion overnight at 37 °C using sequencing grade trypsin (overall 25 ng) (Promega Corporation, WI, Madison), after the addition of 7 µL 1x PBS to each sample. Prior to LC-MS analysis, tryptic HLA-A2-specific IgG glycopeptides were desalted by reverse-phase solid phase extraction, as described (70). Total IgG was captured from

168 plasma/serum using protein G Sepharose Fast Flow 4 beads (GE Healthcare, Uppsala, Sweden), as

169 previously described (71).

170 LC-MS based Fc glycosylation analysis and data processing

Glycopeptides were separated and detected with an Ultimate 3000 high-performance liquid chromatography (HPLC) system (Thermo Fisher Scientific, Waltham, MA) coupled to a maXis quadrupole time-of-flight mass spectrometer (Bruker Daltonics, Billerica, MA), as described (72). Data processing was performed according to established procedures (73).

175 **FcγR binding assay**

The FcγR binding profiles of polyclonal HLA-A2-specific antibodies were defined using the Fc Array
assay described previously (74). Briefly, HLA-A2-coated microspheres were generated as described
above for the multiplex assay, but serum antibodies were detected with FcγRIIIa tetramers formed
by mixing biotinylated FcγRIIIa V158 (75) with a 1/4th molar ratio of Streptavidin-RPE (Agilent, PJ31S1).

181 FcγRIIIa signaling assay

182 As a surrogate for the ADCC potential of the serum-derived and recombinant HLA-A2-specific 183 antibodies, FcyRIIIa signaling was measured by using a Jurkat Lucia NFAT reporter cell line 184 (InvivoGen, jktl-nfat-cd16) (76, 77) in which cross-linking of antigen-bound antibodies and FcyRIIIa 185 leads to the secretion of luciferase into the cell culture supernatant. Levels of Lucia luciferase 186 secreted can then be directly measured by bioluminescence. Briefly, a clear flat bottom, high binding 187 96 well plate (Corning, 3361) was coated with either 1 µg/ml NeutrAvidin (ThermoFisher Scientific, 188 31000) or 1µg/mL biotinylated HLA-A2 antigen via incubation at 4°C overnight. The plates were 189 then washed with 1X phosphate-buffered Saline (PBS) plus 0.05% Tween 20 and blocked with 1x 190 PBS plus 2.5% bovine serum albumin (BSA) for 1 hour at room temperature. HLA-A2 antigen coated 191 plates were directly used, whereas the plates coated first with NeutrAvidin were washed and 192 incubated with 2µg/mL biotinylated HLA-A2 antigen for 1 hour at room temperature. After washing, 193 200 µL of serum diluted 1:100 and 100,000 cells/well in growth medium lacking antibiotics were 194 added and incubated at 37°C for 24 hours. Alternatively, for HLA-A2 mAbs, the plates were first

195 incubated with mAb for 3 hours at room temperature, washed and then was incubated with cells. 196 The following day, 25 µL of supernatant was drawn from each well and then transferred to an 197 opaque, white, clear bottom 96-well plate (Thomas Scientific, 6916A05) to which 75 µL of freshly 198 prepared QuantiLuc (InvivoGen, rep-qlc2) was added. Luminescent was measured immediately on a 199 SpectraMax Paradigm plate reader (Molecular Devices) using 1s of integration time for collecting 200 light. The reported values are the means of three kinetic readings collected at 0, 2.5 and 5 minutes. 201 Treatment of reporter cells with cell stimulation cocktail (ThermoFisher Scientific, 00-4970-93) was 202 used as a positive control, and an $\alpha 4\beta$ 7-specific mAb was used as a negative control. Baseline control 203 wells contained assay medium instead of antibody sample.

204 **FcγR** affinity measurements

205 High Precision Streptavidin 2.0 (SAX2) biosensor tips (Sartorius) were used to determine the kinetics 206 of HLA-A2-specific IgG binding to human FcyRIIIa and FcyRI by biolayer interferometry (BLI) on an 207 Octet (Forte Bio) instrument. Streptavidin (SA) biosensor tips were first loaded with HLA-A2 antigen, 208 followed by HLA-A2 antibody, and finally dipped into FcyR to study the antibody-receptor kinetics. 209 Biosensors were equilibrated with 0.05% Tween-PBS for 60s, loaded with 0.25 µg/mL biotinylated 210 HLA-A2 antigen (in 0.05% Tween-PBS) until they reached the threshold of 1nm, and then dipped 211 into 0.05% Tween-PBS to reach baseline for 60s. After that, the biosensors were loaded with 3µg/mL 212 of recombinant HLA-A2 IgG (in 0.05% Tween-PBS) for 600s, dipped into 0.05% Tween-PBS to reach 213 baseline for 60s, and then dipped into 5µM monomeric FcyRIIIa for 180s or 292 nM FcyRI for 300s 214 for association. To improve signal to noise, serum IgG was purified using Melon gel (Thermo) 215 according to the manufacturer's instructions. Polyclonal serum IgG was loaded for 2400s. For FcyR 216 dissociation rate (kd) determination, two SAX2 biosensor tips were used, one for the measurement 217 and one as a reference to subtract background signal changes due to dissociation of other 218 components, such as dissociation of HLA-A2-specific IgG from biotinylated HLA. Reference 219 biosensors loaded with IgGs were dipped into buffer (0.05% Tween-PBS) instead of receptors. 220 Finally, the sensors were dipped into 0.05% Tween-PBS for 180s and 300s for the dissociation of 221 FcyRIIIa and FcyRI, respectively. Data analysis

222 Data analysis

8

Statistical analysis was performed in GraphPad Prism version 9. Replicates and statistical tests used are reported in figure legends. A nonlinear regression using a one phase exponential decay model was used to fit the dissociation curve and calculate off-rate.

226

227 Results

228 HLA-specific antibody responses were investigated in a cohort consisting of individuals with 229 reported clinical HLA-A2 reactivity (n=32) as detected with a single bead antigen assay, and controls 230 (n=18) with no HLA-A2 reactivity. Among anti-A2 sensitized patients, 28 had received an organ 231 transplant, including 26 kidney transplants and 2 other organs, and 4 patients were on a transplant 232 waiting list (Supplemental Table 1). A2 sensitization was related to previous or current 233 transplantation in 13 patients (41%), pregnancy in 6, blood transfusion in 1 and left ventricular 234 assistance device in 1, whereas the sensitizing event was unknown in 4 patients. AMR was diagnosed 235 in 13/28 (46%) transplanted patients (Supplemental Table 1) and in 7/13 (54%) DSA-positive 236 patients (A2 sensitization in a patient transplanted with an HLA-A2 graft) (Supplemental Table 2). 237 Among controls, 9 patients had no detectable anti-HLA antibodies and 9 had detectable antibodies 238 against non-HLA-A2 antigens. Seventeen controls had received an organ transplant and one was on 239 a transplant waiting list.

240

241 IgG subclass distribution of HLA-specific antibodies

242 We first sought to characterize the subclasses of HLA-specific IgGs in HLA-A2 sensitized and control subjects, using research grade single-antigen bead immunoassays. Briefly, single antigens (intact 243 244 HLA-A02:01 or HLA-A01:01 monomers) were captured on microspheres, and antigen binding of 245 sera samples were measured by multiplex assay. In contrast to the HIV-specific antibody VRC01 246 (negative control), the HLA-A2-specific monoclonal antibody BB7.2 (positive control), which was 247 evaluated in each human IgG subclass, showed specific binding to HLA-A2 (Figure 1A), and 248 appropriate staining by IgG subclass detection reagents (Supplemental Figure 1). In contrast to the 249 negative control mAb, both pooled human serum immunoglobulin (IVIG) and serum from individual

250 control subjects often showed signal considerably above background. While this profile may be 251 consistent with the widespread prevalence of anti-HLA antibodies among healthy individuals (78, 252 79), and responses among subjects clinically defined as HLA-A2 seropositive were significantly 253 elevated as compared to controls, there was a considerable overlap in distributions. Nonetheless, 254 there was a distinct difference observed in the subclass distribution between the two groups, with 255 the HLA-A2 seropositive group generally exhibiting a wide range of total HLA-A2 antibodies as 256 compared to the control samples, which tended to show lower levels (Figure 1A). The wide 257 distribution of HLA-A2 specific IgG signal was consistent with reported values from clinical testing 258 (Supplemental Figure 2), with some samples exhibiting moderate to very low HLA-A2 reactivity. 259 HLA-A2-reactive antibodies predominantly belonged to the IgG1 and IgG2 subclasses, but a few 260 subjects also exhibited higher levels of IgG3 and IgG4; these individuals typically had high levels of 261 total HLA-A2-specific lgG.

262

A similar analysis of HLA-A1-specific antibody levels was performed. The HLA-A2 seropositive group also showed elevated levels of HLA-A1 antibodies as compared to the control group (Figure 1B), again, consistent with clinical single-antigen bead assay results. Interestingly, HLA-A1-specific antibodies predominantly belonged to the IgG2 subclass, with some samples exhibiting higher levels of IgG1, IgG3, and IgG4 subclasses.

268 Affinity-enrichment yields HLA-A2-specific antibodies

269 A microscale purification method was successfully developed and employed for the purification of 270 a control murine HLA-A2 mAb spiked into IVIG (Supplemental Figures 3, 4). Purified antibodies 271 showed elevated reactivity to HLA-A2 antigen, but not to HLA-A1 or to an HSV antigen, which were 272 used as negative controls, confirming the purity of the antibodies. Having vetted the purification 273 process, HLA-A2-specific antibodies were then purified from serum of HLA-A2 antibody positive 274 patients. The purified antibody fractions showed elevated reactivity to HLA-A2, but not to HSV. 275 Despite generally being thought not to possess shared epitopes, the HLA-A2-enriched fraction 276 showed some cross-reactivity with HLA-A1 for a few subjects who were generally strongly positive 277 for both HLA-A1 and HLA-A2 antibodies (based on clinical single antigen bead assay) (Supplemental 278 Figure 5).

279 HLA-A2 specific antibodies exhibit variable degree of afucosylation

280 Having confirmed the largely selective enrichment of HLA-A2-reactive antibodies, next we analyzed 281 Fc glycosylation of both HLA-A2-specific and total serum IgG among HLA-A2 positive individuals. 282 Fc glycosylation analysis revealed differences both on the level of individual glycoforms (Figure 2A, 283 B, C), and overall glycosylation traits including levels of fucosylation, bisection, galactosylation and 284 sialyation (Figure 2D) between HLA-A2-specific and total serum IgG1. Of note, while HLA-A2-285 specific antibody Fc fucosylation of some individuals was comparable to that of total IgG1, others 286 exhibited fucosylation levels reduced by 5-15%, or even 30% as compared to their total IgG1 287 counterpart (Figure 2D). HLA-A2 specific IgG2/3 was characterized by higher bisection, 288 galactosylation and sialylation than total serum IgG2/3, but no afucosylated IgG2/3 glycopeptides 289 were detected (Figure 2D). Consistent with multiplex assay data, antigen-specific IgG4 responses 290 were generally too low to be robustly characterized by LC-MS. While IgG2 and IgG3 glycopeptides 291 could not be distinguished by mass spectrometry due to their identical molecular mass, the high 292 levels of antigen-specific IgG2 and low levels of IgG3 observed suggest that the antigen-specific 293 IgG2/3 glycosylation signatures were dominated by IgG2.

294 Afucosylated HLA-A2-specific mAbs exhibit enhanced FcyRIIIa signaling

To study the Fc**q**R signaling characteristics of HLA-A2-specific antibodies, we produced afucosylated BB7.2 IgG1 and IgG3 mAbs and assessed signaling driven by ligation of Fc**q**RIII, a receptor typically expressed by NK cells, in a reporter cell line (77) as a surrogate for ADCC activity. IgG1 and IgG3 isotypes of BB7.2 were found to show Fc**q**RIIIa ligation and signaling activity, whilst neither the control IgG1 subclass nor IgG2 and IgG4 subclasses of BB7.2 showed activity above baseline (**Figure 3A**). As expected, afucosylated IgG1 and IgG3 demonstrated considerably enhanced Fc**q**RIII signaling activity as compared to their non-glycoengineered counterparts.

302 Enhanced FcyRIII signaling is associated with slow antibody dissociation

303 To address the mechanism of improved Fc**y**RIIIa signaling activity, we next sought to characterize 304 the interaction between HLA-A2-specific antibodies and Fc**y**RIIIa using Biolayer Interferometry (BLI) 305 (**Figure 3B, Supplemental Figure 6**), a label free technique commonly used to study the affinity and

306 kinetics of protein-protein interactions. Antibodies bound to HLA-A2 antigen were allowed to bind

307 (t = 0 to 120s) and then dissociate (t = 120-240s) from Fc γ RIIIa V158. All mAbs exhibited the fast on-308 rate typical of Fc γ R and showed similar levels of Fc γ RIIIa binding signal (**Figure 3C**). In contrast, 309 dissociation rates (k_d) varied by more than an order of magnitude between fucosylated and 310 afucosylated mAbs (**Figure 3C**). We found that afucosylated IgG1 and IgG3 had slower dissociation 311 rates (mean k_d = 0.021 s⁻¹) as compared to unmodified forms (mean k_d = 0.46 s⁻¹). This difference in 312 dissociation rate was specific for Fc γ RIIIa, as fucosylation did not influence Fc γ RI binding 313 (**Supplemental Figure 7**), as expected (63).

314 Serum HLA-A2 specific antibody fucosylation associates with FcγRIIIa dissociation and ligation

315 Since afucosylated HLA-A2-specific mAbs had slower dissociation from FcyRIIIa as compared to their 316 unmodified counterparts, we next studied the dissociation profiles of polyclonal HLA-A2 specific 317 antibodies in human serum and found FcyRIIIa dissociation rate to be positively associated with 318 fucosylation (Figure 4A). The variable off-rates observed among differentially fucosylated serum-319 derived HLA-A2-specific antibodies suggested that FcyRIIIa ligation and signaling profiles of these 320 HLA-A2 specific antibodies might also vary. To test this possibility, HLA-A2 seropositive subjects 321 were split into tertiles (high, medium, and low) based on their HLA-A2-specific antibody fucosylation 322 levels (Figure 4B). A multiplex assay was conducted, in which HLA-A2-specific antibodies were 323 evaluated for their ability to bind FcyRIIIa tetramers (74). Although there was no significant 324 difference in FcyRIIIa binding between high, medium, and low fucose tertiles, HLA-A2 specific 325 antibodies in each of these three categories had higher FcyRIIIa binding as compared to negative 326 controls, as exemplified by the observed negative correlations (Figure 4B). In line with observations 327 on variably fucosylated mAbs, these results demonstrate that human serum-derived HLA-A2-specific 328 antibodies with low fucosylation exhibit improved FcyRIIIa binding.

329 Serum HLA-A2 specific antibody fucosylation associates with functional activity

330 To understand how antibody fucosylation level was related to FcγRIIIa signaling, a limited correlation 331 analysis was performed. Both HLA-A2-specific antibody titers and the FcγRIIIa ligation activity 332 determined by multiplex assay were negatively associated with fucosylation (Figure 4C), and 333 positively associated with FcγRIIIa signaling (Figure 4D). Despite the low signaling activity observed 334 across experimental replicates in the reporter cell line assay (Supplemental Figure 8A), relationships

between FcyRIIIa signaling measured were consistently correlated to polyclonal HLA-A2-specific
 antibody titer and FcyRIIIa binding (Supplemental Figure 8B).

337 HLA-A2-specific antibody afucosylation was correlated with clinical AMR

338 To explore how HLA-A2 specific antibody characteristics relate to transplantation outcomes, patient 339 data was analyzed based on AMR status. Subjects with AMR tended to have high HLA-A2 antibody 340 titer and low HLA-A2-specific IgG1 fucosylation, thereby showing high FcyRIIIa binding, high 341 signaling activity, and slower dissociation from FcyRIIIa (Figure 4). As a more direct test, we analyzed 342 HLA-A2 specific antibody features between subjects with and without AMR. Whether or not HLA-343 A2 represented a DSA, individuals with AMR showed significantly lower levels of HLA-A2-specific 344 IqG1 fucosylation as compared to the individuals who did not have clinically defined AMR (Figure 345 5A), suggesting that a low level of HLA-A2-specific antibody fucosylation may be a marker of AMR 346 in kidney transplant patients. Other features, including HLA-A2-specific antibody titer, did not show 347 such differences according to AMR status (Supplemental Figure 9).

348

In order to further examine the correlation between afucosylation of DSA and clinical AMR outcomes we analyzed subjects who had anti-HLA-A2 as a DSA. Patients who developed AMR had "low" and "moderate" fucose content of HLA-A2-specific DSA, whereas patients who did not develop AMR had "high" fucose content of HLA-A2-specific DSA. (**Figure 5B**). Collectively, this data suggests that the phenotypic variability among anti-HLA-A2 antibody responses may have an important influence on organ transplant outcomes.

355

356 Discussion

The last two decades have witnessed a considerable increase in understanding immunological processes related to organ rejection, which has contributed to reduction in the incidence of acute rejection and improvement in short-term graft survival (23, 80-82). Despite the advances in immunosuppression strategies, HLA matching, and better management of acute rejection, the prognosis for long-term graft outcome remains one of the biggest challenges in the field of organ

transplantation (2). Given the well-established importance of qualitative aspects of the antibody response in other settings, consideration of antibody subclass, Fc glycosylation, and FcγR binding in the context of renal transplant outcomes will define the importance of these features in mediating functions that escalate the risk of organ rejection (2). Discovery of robust relationships between features of DSA and transplant outcomes has the potential to drive revision of clinical strategies of organ allocation as well as development of novel interventions.

368

To date, relatively few studies have looked at DSA subclass and Fc glycosylation in kidney transplant recipients. Challenges in DSA purification from plasma/serum appear to have posed a major hurdle to its glycosylation analysis, resulting in a focus on characterization of total serum IgG glycosylation (83-85). In this study, we employed a microscale purification method to purify HLA-A2-specific antibodies from patient sera and set out to evaluate IgG subclass and Fc glycosylation profiles thereof. Both of these features regulate Fc-Fc**γ**R interactions, which in turn potentially relate to pathogenicity and graft rejection.

376

377 Beyond the complexity of the many processes associated with allograft injury and rejection, 378 phenotypic changes in DSA over time have also been observed (43), complicating the understanding 379 of the pathophysiology of rejection. What has become clear is that DSA titers, subclass profiles or 380 C1q binding activity alone are insufficient to accurately predict the course of AMR, and the field 381 remains in need of reliable prognostic biomarkers to guide treatment, optimally allocate organs, and 382 reduce the risk of rejection in DSA-sensitized recipients.

383

384 Though not strongly associated with outcomes of organ rejection, IgG subclass is known to strongly 385 modify the ability of antibodies to drive complement deposition and recruit the innate immune 386 effector cells that mediate clearance of opsonized particles (5, 27, 29, 43, 86). HLA-A2-specific 387 responses in clinically seropositive subjects were predominantly IgG1 and IgG2. High levels of IgG1 388 antibodies suggest the possibility of elevated Fc mediated effector functions, such as phagocytosis, 389 ADCC and complement deposition (63), which might lead to severe graft injury and transplant 390 rejection. The prevalence of HLA-A1-specific IgG2 antibodies in this population suggests that the 391 IgG subclass profile can vary from one HLA antigen to another even within a given individual,

highlighting the potential importance of integrating profiles across diverse specificities and
 characterizing features of anti-HLA antibodies beyond titer.

394

395 Antibody effector functions are highly affected by the composition of the N-glycan present at the 396 conserved N-glycosylation site in the Fc region (60, 61, 87-89). Hitherto, it has been repeatedly 397 shown that disease-specific antibodies can exhibit skewed glycosylation profiles, that in turn 398 associate with disease prognosis and outcome (73, 90-93). Historically, one of the key limitations of 399 glyco-profiling such antibodies is their low serum prevalence and high sample requirement. In order 400 to facilitate Fc glycosylation analysis of low abundant HLA-A2 specific antibodies, an antigen-specific 401 antibody purification approach was developed for reliable, sensitive, and specific capturing of HLA-402 A2 specific antibodies from reactive sera. This platform was leveraged to support analysis of HLA-403 A2-specific IgG Fc glycosylation profiles. As compared to the global serum IgG profiles, we observed 404 variable degree of HLA-A2 specific IgG1s afucosylation. This feature was associated with improved 405 FcyRIIIa binding as afucosylation has been described to lead to elevated FcyRIII binding (58, 63, 83-406 86), we hypothesized that low HLA-A2-specific IgG1 fucosylation could cause elevated DSA 407 cytotoxicity via enhanced ADCC. Indeed, when tested in the context of a subclass-switched 408 recombinant antibody specific for HLA-A2, both subclass and fucosylation had a strong impact on 409 FcyRIIIa affinity and signaling. Specifically, afucosylated mAbs had slower dissociation from the 410 receptor, which could provide sufficient time for the receptors to cross-link and activate downstream 411 signaling pathways and modulate ADCC. This relationship was also observed among polyclonal 412 HLA-A2-specific antibodies purified from patient sera, and suggests that afucosylated antibodies to 413 HLA-A2 can exhibit elevated ADCC activity, as shown in other disease settings (70, 92, 94-96), and 414 raises the possibility that DSA glycosylation may provide prognostic value in predicting risk of AMR. 415 Indeed, individuals who had AMR exhibited low levels of HLA-A2 specific IgG1 fucosylation as 416 compared to the individuals who did not have AMR, suggesting that low HLA-A2 IgG1 fucosylation 417 may be a marker of AMR risk in kidney transplant patients. Despite small cohort size, among 418 individuals in whom HLA-A2 represented a DSA, low HLA-A2 specific IgG1 antibody fucosylation 419 was associated with AMR.

420

421 While this work suggests the potential role of IgG Fc fucosylation and its influence on DSA 422 pathogenicity, it is likely that more systematic serology data, considering antibody titer, subclass, 423 glycans, epitope specificity, antigen-specificity, and affinity, linked to clinical metadata and insights 424 into host- and graft-specific genetic and phenotypic factors will be needed for comprehensive 425 understanding. The experimental tools explored here will need to be broadened to cover the 426 diversity of DSA specificities that contribute to clinical outcomes. Similarly, analytical approaches 427 (97-99) that integrate across features of the humoral response, and that can robustly address 428 correlations among features, such as those observed here between titer and afucosylation, may 429 contribute to discovery of mechanisms underlying graft injury and AMR. To this end, the subclass-430 switched and glycoengineered mAbs described herein may support dissection of the mechanistic 431 role of these features in AMR studies in animal models.

432

433 Limitations of this study include its focus on a single antigen-specificity and antibody function, 434 limited outcome data and reliance on a relatively small group of HLA-A2 seropositive subjects. The 435 lack of a clear boundary between seropositive and seronegative subjects based on clinical testing 436 suggests that positivity determinations may be quite sensitive to different reagents, tests, and 437 thresholds, as well as to differences in antigen density and loaded antigens between single antigen 438 beads and research microspheres applied by different clinical groups. A reporter cell line and 439 recombinant HLA-A2 antigen, as opposed to primary effector and HLA-A2-expressing target cells 440 were used to evaluate FcyRIIIa signaling as a proxy for cytotoxicity, degranulation, and release of 441 other inflammatory mediators that may be relevant to graft damage. Antibody clonality, fine epitope 442 specificity, and affinity for HLA-A2 were not assessed. Despite extensive condition testing, signals 443 in the reporter cell line assay were low for both mAbs and polyclonal sera samples, and despite their 444 correlations with other activities, were not always elevated in comparison to the control sera. 445 Similarly, while signals in the in-house multiplex assay were correlated with clinical test results, 446 agreement was less good than we have observed in other multiplexed assays, and distributions 447 overlapped with those observed among control sera, perhaps in association with the rate of 448 seropositivity in healthy populations (78, 79). While similar yields were observed to result from 449 affinity purification against HLA-A2 with each of two different peptides in a pilot experiment, 450 peptide occupancy and identity may also impact results of the assays used. Lastly, while a direct

451 association has been made between afucosylation of DSA and the occurrence of AMR, HLA-A2-452 specific antibodies were first detected in most of the patients post-rejection, suggesting that 453 afucosylation of DSA may have occurred as a result of AMR. Future studies will benefit from larger 454 and longitudinal cohorts that include samples collected pre-AMR, that are more homogenous in 455 relevant clinical characteristics, and designs that are targeted to address relationships with 456 transplant outcomes.

457

458 Overall, despite considerable clinical heterogeneity of the study population, HLA-A2-specific IgG 459 fucosylation was associated with FcyRIIIa binding and function. Different HLA reactivities showed 460 distinct subclass profiles, and the dominant IgG1 fraction of HLA-A2-specific IgG showed reduced 461 fucosylation as compared to total serum IgG1. Along with antibody titer, reduced fucosylation was 462 associated with elevated binding to, and slower dissociation from FcyRIIIa. Afucosylation of HLA-463 A2-specific antibodies was also associated with potentiated signaling through FcyRIIIa. HLA-A2-464 specific IgG1 Fc fucose content was associated with AMR status among the subset of subjects for 465 whom this specificity represented a DSA as well among those where it did not, leaving important 466 guestions unresolved about the importance of this antibody feature in mediating AMR. Further and 467 prospective studies will be needed to confirm the role of afucosylation in the pathophysiology of 468 AMR, and continued customization and broader deployment of these and other systems serology 469 approaches has the potential to shed light on the clinical impact of qualitative antibody features and 470 activities on graft damage.

471

472 Author contributions

P.B.: writing - original draft, investigation, data curation, visualization, methodology, validation; S.S.:
writing - original draft, investigation, data curation, validation, visualization; T.P.: writing – review &
editing, investigation, data curation, validation, visualization; C.C.: , S.S.: , A.L.M.: ; N. de H.: writing
review & editing, supervision; N.M.: writing- review & editing, supervision; L.V.R.: ; M.W.: writing
review & editing, funding acquisition, supervision; A.M.: , M.E.A.: conceptualization, supervision,
funding acquisition, writing – review & editing.

479

480 Acknowledgements

- 481 We want to thank Andreia Isabel Ferreira Verissimo and Emilie Shipman from bioMT- Institute for
- 482 Biomolecular Targeting at Dartmouth. The authors also thank Carolien Koeleman for expert
- 483 technical assistance. We thank all members of the HLA Laboratory, Laboratoire Hospitalier
- 484 Universitaire de Bruxelles (LHUB), and Dr Sanâa El Korchi, Erasme Hospital ULB, Brussels,
- 485 Belgium, for expert assistance in clinical data and sample management and in clinical
- 486 sample testing. We thank the NIH Tetramer Core Facility (contract number 75N93020D00005) for
- 487 providing HLA monomers.

488

489 Funding

490 Variably fucosylated IgG was produced by the Dartmouth bioMT- Institute for Biomolecular 491 Targeting (NIGMS COBRE award P20-GM113132). T. P. has received funding from the European 492 Union's Horizon 2020 Research and Innovation Programme, under H2020-MSCA-ITN grant 493 agreement number 721815. C.C has received funding from the Fonds National de la Recherche 494 Scientifique (FNRS), Belgium, and from the Fonds Erasme, Belgium.

495

496 Competing interests

PB, SS, TP, ALM, NdeH, MW, AM, and MEA are named inventors on a provisional patent application
related to this work.

499

- 500 Data availability statement
- 501 The dataset generated for this study is available at (link pending).

502

503 Abbreviations

- 504 ADCC Antibody-dependent cellular cytotoxicity
- 505 AMR Acute-mediated rejection
- 506 BLI Biolayer Interferometry
- 507 DSA Donor specific antibody
- 508 Fc Fragment crystallizable
- 509 HLA Human leukocyte antigen
- 510 IgG Immunoglobulin G
- 511 IVIG Intravenous immunoglobulin G
- 512 MFI Mean Fluorescent Intensity
- 513 R receptor

514 **References**

- Thongprayoon C, Hansrivijit P, Leeaphorn N, Acharya P, Torres-Ortiz A, Kaewput W et al. Recent
 Advances and Clinical Outcomes of Kidney Transplantation. Journal of Clinical Medicine
 2020;9(4):1193.
- Chong AS, Rothstein DM, Safa K, Riella LV. Outstanding questions in transplantation: B cells,
 alloantibodies, and humoral rejection. American Journal of Transplantation 2019;19(8):2155 2163.
- Cheng EY, Everly MJ, Kaneku H, Banuelos N, Wozniak LJ, Venick RS et al. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients. Transplantation 2017;101(4):873-882.
- Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients.
 Transplantation Reviews 2017;31(1):47-54.
- 526 5. Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: 527 manifestations, mechanisms, and therapies. The Journal of clinical investigation 528 2017;127(7):2492-2504.
- 529 6. Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the
 530 21st century. Annals of Translational Medicine 2018;6(20):409-409.
- Gebel HM, Kasiske BL, Gustafson SK, Pyke J, Shteyn E, Israni AK et al. Allocating Deceased
 Donor Kidneys to Candidates with High Panel-Reactive Antibodies. Clinical journal of the
 American Society of Nephrology : CJASN 2016;11(3):505-511.
- Sensitized PRA (CPRA): The New Measure of Sensitization for Transplant Candidates:
 Sensitized Patients, PRA and CPRA. American Journal of Transplantation 2009;10(1):26-29.
- Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O et al. Value of Donor Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney
 Allograft Loss. Journal of the American Society of Nephrology : JASN 2016;28(2):702-715.
- 539 10. Terasaki PI, Ozawa M. Predicting Kidney Graft Failure by HLA Antibodies: a Prospective Trial:
 540 Prediction of Failure by Antibodies. American Journal of Transplantation 2004;4(3):438-443.
- 541 11. Timofeeva OA. Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection. Clinics in
 542 Laboratory Medicine 2018;39(Am J Transplant 14 2 2014):45-60.
- 543 12. Ghandorah S, Yilmaz S, Abadi A, Rahmanian T, Wang J, Khan FM et al. Characteristics of donor 544 specific anti-HLA antibodies in renal transplant recipients. Human Immunology 2015;76:163.
- 545 13. Visentin J, Marroc M, Guidicelli G, Bachelet T, Nong T, Moreau J-F et al. Clinical impact of
 546 preformed donor-specific denatured class I HLA antibodies after kidney transplantation. Clinical
 547 Transplantation 2015;29(5):393-402.
- 548 14. Böhmig GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody 549 mediated kidney allograft rejection. Transplant International 2019;32(8):775-788.
- 550 15. Salvadori M, Bertoni E. Acute Antibody-Mediated Rejection in Kidney Transplantation: Clinical
 and Therapeutic Aspects. Journal of Nephrology & Therapeutics 2013;04(01).
- 552 16. Sellarés J, Reeve J, Loupy A, Mengel M, Sis B, Skene A et al. Molecular Diagnosis of Antibody 553 Mediated Rejection in Human Kidney Transplants. American Journal of Transplantation
 554 2013;13(4):971-983.
- 17. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen J-PP, Suberbielle C, Anglicheau D et al.
 Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet
 (London, England) 2013;381(9863):313-319.

- 18. Butler CL, Valenzuela NM, Thomas KA, Reed EF. Not All Antibodies Are Created Equal: Factors
 That Influence Antibody Mediated Rejection. Journal of Immunology Research 2017;2017:1-9.
- 560 19. Alelign T, Ahmed MM, Bobosha K, Tadesse Y, Howe R, Petros B. Kidney Transplantation: The
- 561 Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. Journal of Immunology 562 Research 2018;2018:1-18.
- 20. Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L et al. De Novo Donor-Specific
 Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Kidney Transplant Recipients: PostHoc Analyses of the Randomized Phase III BENEFIT and BENEFIT-EXT Studies. American journal
 of transplantation : official journal of the American Society of Transplantation and the American
 Society of Transplant Surgeons 2018;18(7):1783-1789.
- Severova G, Nikolov I, Sikole A, Cakalaroski K, Popov Z, Ivanovski N. Clinical Importance of Non Donor-Specific HLA Antibodies and Possible Impact on Graft Histology in Kidney Transplant
 Recipients 12 Months Protocol Biopsy Study. Transplantation 2018;102(&NA;):S484.
- 571 22. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP et al. Incidence and Impact
 572 of De Novo Donor-Specific Alloantibody in Primary Renal Allografts. Transplantation Journal
 573 2013;95(3):410-417.
- 574 23. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S et al. OPTN / SRTR 2018 Annual
 575 Data Report: Kidney. American Journal of Transplantation 2020;20(s1):20-130.
- 576 24. Kwun J, Knechtle S. Experimental modeling of desensitization: What have we learned about
 577 preventing AMR? American Journal of Transplantation 2020;20(S4):2-11.
- 578 25. Chandra A, Midtvedt K, Åsberg A, Eide IA. Immunosuppression and Reproductive Health After
 579 Kidney Transplantation. Transplantation 2019;103(11):e325-e333.
- 580 26. Kramer CSM, Dijk MEIFv, Priddey AJ, Pongrácz T, Gnudi E, Car H et al. Recombinant human
 581 monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent
 582 tools to study differential effects of donor-specific antibodies. HLA 2019;94(5):415-424.
- 27. Lefaucheur C, Viglietti D, Bentlejewski C, Huyen J-PDv, Vernerey D, Aubert O et al. IgG Donor Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.
 Journal of the American Society of Nephrology 2016;27(1):293-304.
- 586 28. Valenzuela NM, Hickey MJ, Reed EF. Antibody Subclass Repertoire and Graft Outcome
 587 Following Solid Organ Transplantation. Frontiers in immunology 2016;7:433.
- 588 29. O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3
 589 Subclass and C1q-Fixing Donor-Specific HLA Alloantibodies on Rejection and Survival in Liver
 590 Transplantation. American Journal of Transplantation 2015;15(4):1003-1013.
- 30. Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT et al. Impact of IgM and
 IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients. Transplantation
 2014;97(5):494-501.
- 594 31. Freitas MCS, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M et al. The Role of
 595 Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney
 596 Transplantation Outcomes. Transplantation Journal 2013;95(9):1113-1119.
- 32. Gunn BM, Roy V, Karim MM, Hartnett JN, Suscovich TJ, Goba A et al. Survivors of Ebola Virus
 Disease Develop Polyfunctional Antibody Responses. The Journal of Infectious Diseases
 2019;221(1):156-161.
- 33. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in
 infectious diseases. Nature Reviews Immunology 2018;18(1):46-61.

- 34. Plomp R, Ruhaak RL, Uh H-W, Reiding KR, Selman M, Houwing-Duistermaat JJ et al. Subclassspecific IgG glycosylation is associated with markers of inflammation and metabolic health.
 Scientific Reports 2017;7(1):12325.
- 35. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK et al. IgG antibodies
 to dengue enhanced for FcγRIIIA binding determine disease severity. Science
 2017;355(6323):395-398.
- 36. Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z et al. Increased levels of
 galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005;19(4):381-389.
- 37. Raux M, Finkielsztejn L, Salmon-Cron D, Bouchez H, Excler JL, Dulioust E et al. IgG Subclass
 Distribution in Serum and Various Mucosal Fluids of HIV Type 1-Infected Subjects. AIDS Research
 and Human Retroviruses 2000;16(6):583-594.
- 38. Kapur R, Kustiawan I, Vestrheim A, Koeleman CA, Visser R, Einarsdottir HK et al. A prominent
 lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014;123(4):471-480.
- 39. Bakchoul T, Greinacher A, Sachs UJ, Krautwurst A, Renz H, Harb H et al. Inhibition of HPA-1a
 alloantibody-mediated platelet destruction by a deglycosylated anti–HPA-1a monoclonal
 antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood
 2013;122(3):321-327.
- 40. Sellarés J, Freitas DGd, Mengel M, Reeve J, Einecke G, Sis B et al. Understanding the causes of
 kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
 American journal of transplantation : official journal of the American Society of Transplantation
 and the American Society of Transplant Surgeons 2011;12(2):388-399.
- 41. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C et al. Preexisting donor-specific
 HLA antibodies predict outcome in kidney transplantation. Journal of the American Society of
 Nephrology : JASN 2010;21(8):1398-1406.
- 42. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J et al. Outcome of
 subclinical antibody-mediated rejection in kidney transplant recipients with preformed donorspecific antibodies. American journal of transplantation : official journal of the American Society
 of Transplantation and the American Society of Transplant Surgeons 2009;9(11):2561-2570.
- 43. Khovanova N, Daga S, Shaikhina T, Krishnan N, Jones J, Zehnder D et al. Subclass analysis of
 donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant
 association of IgG4 with rejection and graft failure. Transplant International 2015;28(12):14051415.
- 44. Grafals M, Thurman JM. The Role of Complement in Organ Transplantation. Frontiers inImmunology 2019;10:2380.
- 45. Navas A, Molina J, Agüera M-L, Guler I, Jurado A, Rodríguez-Benot A et al. Characterization of
 the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by
 Solid-Phase Assays. Frontiers in Immunology 2019;10:1712.
- 639 46. Thurman JM, Panzer SE, Quintrec ML. The role of complement in antibody mediated transplant
 640 rejection. Molecular Immunology 2019;112:240-246.
- 641 47. Biglarnia A-R, Huber-Lang M, Mohlin C, Ekdahl KN, Nilsson B. The multifaceted role of
 642 complement in kidney transplantation. Nature Reviews Nephrology 2018;14(12):767-781.
- 48. Lee H, Han E, Choi A-R, Ban T, Chung B, Yang C et al. Clinical impact of complement (C1q, C3d)
 binding De Novo donor-specific HLA antibody in kidney transplant recipients. PLOS ONE
 2018;13(11):e0207434.

- 646 49. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N et al.
 647 Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med
 648 2013;369(13):1215-1226.
- 50. Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V et al. Non-ComplementBinding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. J Am Soc
 Nephrol 2016;27(2):615-625.
- 51. Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirao I et al. Determining donor-specific
 antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human
 leucocyte antigen-incompatible kidney transplantation. Transpl Int 2017;30(4):347-359.
- 52. Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J et al. Rates and Determinants
 of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific
 Antibody: Post- dn DSA Clinical Histologic Progression. American Journal of Transplantation
 2015;15(11):2921-2930.
- 53. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ et al. Evolution and Clinical
 Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant:
 Clinical Pathologic Correlations of De Novo DSA. American Journal of Transplantation
 2012;12(5):1157-1167.
- 54. Yamashita M, Haas M. Transplant Glomerulopathy with Glomerular C3 Deposits: Why the Worse
 Outcome? Kidney International Reports 2019;4(Transplant glomerulopathy. Am J Transplant 8
 2008):516-519.
- 55. Molina J, Navas A, Agüera M-L, Rodelo-Haad C, Alonso C, Rodríguez-Benot A et al. Impact of
 Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on
 Kidney Allograft Outcome. Frontiers in Immunology 2017;8:1310.
- 56. Gupta G, Jawdeh BGA, Racusen LC, Bhasin B, Arend LJ, Trollinger B et al. Late antibodymediated rejection in renal allografts: outcome after conventional and novel therapies.
 Transplantation 2014;97(12):1240-1246.
- 57. Piazza A, Poggi E, Ozzella G, Adorno D. Post-transplant development of C1q-positive HLA
 antibodies and kidney graft survival. Clinical transplants 2013:367-375.
- 58. Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation. Journal of
 Clinical Investigation 2019;129(9):3492-3498.
- 59. Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML. Fc-galactosylation modulates
 antibody-dependent cellular cytotoxicity of therapeutic antibodies. Molecular Immunology
 2016;73:69-75.
- 679 60. Abès R, Teillaud J-L. Impact of Glycosylation on Effector Functions of Therapeutic IgG †.
 680 Pharmaceuticals 2010;3(1):146-157.
- 681 61. Raju ST. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Current
 682 Opinion in Immunology 2008;20(4):471-478.
- 683 62. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M et al. The Absence
 684 of Fucose but Not the Presence of Galactose or Bisecting N -Acetylglucosamine of Human IgG1
 685 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent
 686 Cellular Cytotoxicity. Journal of Biological Chemistry 2002;278(5):3466-3473.
- 687 63. Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM et al. Decoding the
 688 Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and
 689 Complement-Mediated-Effector Activities. Front Immunol 2017;8:877.

- 64. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D et al. The Banff 2017 Kidney
 Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection,
 antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical
 trials. Am J Transplant 2018;18(2):293-307.
- 65. Babrak L, McGarvey JA, Stanker LH, Hnasko R. Identification and verification of hybridoma derived monoclonal antibody variable region sequences using recombinant DNA technology
 and mass spectrometry. Molecular Immunology 2017;90:287-294.
- 697 66. Taeye SWd, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D et al.
 698 FcγR Binding and ADCC Activity of Human IgG Allotypes. Frontiers in Immunology 2020;11:740.
- 67. Dekkers G, Plomp R, Koeleman CAM, Visser R, Horsten HHv, Sandig V et al. Multi-level glycoengineering techniques to generate IgG with defined Fc-glycans. Scientific Reports
 2016;6(1):36964.
- 68. Brown EP, Normandin E, Osei-Owusu N, Mahan AE, Chan YN, Lai JI et al. Microscale purification
 of antigen-specific antibodies. Journal of Immunological Methods 2015;425:27-36.
- 69. Brown EP, Licht AF, Dugast A-S, Choi I, Bailey-Kellogg C, Alter G et al. High-throughput,
 multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. Journal of
 immunological methods 2012;386(1):117-123.
- 707 70. Kapur R, Della Valle L, Sonneveld M, Hipgrave Ederveen A, Visser R, Ligthart P et al. Low anti 708 RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease
 709 of the fetus and newborn. Br J Haematol 2014;166(6):936-945.
- 710 71. Falck D, Jansen BC, de Haan N, Wuhrer M. High-Throughput Analysis of IgG Fc Glycopeptides
 711 by LC-MS. Methods Mol Biol 2017;1503:31-47.
- 712 72. de Haan N, Reiding KR, Kristic J, Hipgrave Ederveen AL, Lauc G, Wuhrer M. The N-Glycosylation
 713 of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and
 714 Strains. Front Immunol 2017;8:608.
- 715 73. Pongracz T, Nouta J, Wang W, van Meijgaarden KE, Linty F, Vidarsson G et al. Immunoglobulin
 716 G1 Fc glycosylation as an early hallmark of severe COVID-19. medRxiv 2021.
- 717 74. Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T et al. Multiplexed Fc array
 718 for evaluation of antigen-specific antibody effector profiles. J Immunol Methods 2017;443:33719 44.
- 720 75. Boesch AW, Brown EP, Cheng HD, Ofori MO, Normandin E, Nigrovic PA et al. Highly parallel
 721 characterization of IgG Fc binding interactions. MAbs 2014;6(4):915-927.
- 722 76. Thulin NK, Brewer RC, Sherwood R, Bournazos S, Edwards KG, Ramadoss NS et al. Maternal
 723 Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants. Cell Reports
 724 2020;31(6):107642.
- 725 77. Butler SE, Crowley AR, Natarajan H, Xu S, Weiner JA, Bobak CA et al. Distinct Features and
 726 Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent
 727 Individuals. Frontiers in Immunology 2021;11:618685.
- 728 78. Elkhalifa MY, Alhababi D, Saleh SA, Khan A, Ashur Z, Alshaibi N. P221 "Naturally occuring" anti 729 HLA antibodies. Hum Immunol 2017;78.
- 730 79. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J. "Natural"
 731 human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation
 732 2008;86(8):1111-1115.
- 80. Beyar R. Challenges in organ transplantation. Rambam Maimonides Med J 2011;2(2):e0049e0049.

- 81. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C et al. A study of the quality of life
 and cost-utility of renal transplantation. Kidney Int 1996;50(1):235-242.
- 82. Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. Desensitization: Overcoming the
 Immunologic Barriers to Transplantation. J Immunol Res 2017;2017:6804678.
- 739 83. Tait BD. Detection of HLA Antibodies in Organ Transplant Recipients Triumphs and Challenges
 740 of the Solid Phase Bead Assay. Frontiers in Immunology 2016;7:570.
- 84. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen–specific antibodies.
 Hum Immunol 2008;69(10):591-604.
- 85. Malard-Castagnet S, Dugast E, Degauque N, Pallier A, Soulillou JP, Cesbron A et al. Sialylation
 of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody
 mediated rejection. Hum Immunol 2016;77(11):1076-1083.
- 86. Arnold ML, Ntokou IS, Doxiadis, II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA
 antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from
 complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
 Transpl Int 2014;27(3):253-261.
- 750 87. Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol
 751 2017;38(5):358-372.
- 88. Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function
 by Fc glycan engineering. Proc Natl Acad Sci U S A 2017;114(13):3485-3490.
- 89. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector
 functions. Front Immunol 2014;5:520.
- 90. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ et al. Natural variation in Fc
 glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013;123(5):21832192.
- 91. Bournazos S, Vo Hoa Thi M, Duong V, Auerswald H, Ly S, Sakuntabhai A et al. Antibody
 fucosylation predicts disease severity in secondary dengue infection. Science
 2021;372(6546):1102-1105.
- 92. Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W et al. Afucosylated IgG
 characterizes enveloped viral responses and correlates with COVID-19 severity. Science
 2021;371(6532).
- 93. Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol
 2018;333:65-79.
- 94. Hoepel W, Chen HJ, Geyer CE, Allahverdiyeva S, Manz XD, de Taeye SW et al. High titers and
 low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar
 macrophages. Sci Transl Med 2021;13(596).
- 95. Kapur R, Kustiawan I, Vestrheim A, Koeleman CA, Visser R, Einarsdottir HK et al. A prominent
 lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014;123(4):471-480.
- 96. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK et al. IgG antibodies
 to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science
 2017;355(6323):395-398.
- 97. Ackerman ME, Barouch DH, Alter G. Systems serology for evaluation of HIV vaccine trials.
 Immunol Rev 2017;275(1):262-270.
- 98. Alter G, Dowell KG, Brown EP, Suscovich TJ, Mikhailova A, Mahan AE et al. High-resolution
 definition of humoral immune response correlates of effective immunity against HIV. Mol Syst
 Biol 2018;14(3):e7881-e7881.

- 780 99. Loos C, Lauffenburger DA, Alter G. Dissecting the antibody-OME: past, present, and future.
- 781 Current Opinion in Immunology 2020;65:89-96.

782

Figures and Legends



Figure 1. Subclass distribution of HLA specific antibodies. Characterization of HLA-specific antibodies binding to HLA-A2 (A) and HLA-A1 (B) antigens across IgG subclasses in HLA-A2 positive (black circles; n=30-32) and control (gray circles; n=18) individuals. HLA-A2-specific BB7.2 (square) and HIV-specific VRCO1 (triangle) mAb subclass controls for HLA-A2 reactivity are shown for each subclass: IgG1 (light blue), IgG2 (orange), IgG3 (dark blue) and IgG4 (red). Buffer only blank (cross) and pooled IVIG (diamond) are shown in brown and purple, respectively. Serum samples were tested at a 1:100 dilution. Data shown are representative of two technical replicates. Solid red lines indicate group median. Differences between groups were evaluated using Ordinary Two-way ANOVA adjusted for multiple comparisons using Bonferroni's test (**p<0.001, ***p<0.001, ***p<0.0001, respectively).



Figure 2. Fc glycosylation of HLA-A2-specific antibodies. Representative extracted ion chromatograms and mass spectra (A, B) illustrating the observed variability between HLA-A2-specific (A) and total (B) IgG1 Fc glycosylation patterns of the same patient. C. Volcano plot displaying the log₁₀ fold change (x-axis) and -log₁₀ *p*-value (y-axis) of individual IgG1 (blue circle) and IgG2/3 (maroon square) glycoforms between total and HLA-A2-specific IgG1 and IgG2/3, respectively. D. Violin plots showing the relative prevalence of glycans on bulk and HLA-A2 specific IgG1 (top) and IgG2/3 (bottom), respectively. Statistical analysis was performed using a paired two-tailed Student's t-test (**: p<0.01, ***: p<0.001, ****: p<0.0001, respectively).



Figure 3. Impact of HLA-A2 specific mAb fucosylation on Fc γ RIIIa binding and signaling per subclass. A. Fc γ RIIIa signaling in a reporter cell line assay with unmodified and afucosylated HLA-A2 mAbs of varying subclasses. B. Schematic figure of the BLI experiment to define Fc γ RIIIa off-rates from HLA-A2-specific antibodies. Illustration created with <u>http://BioRender.com</u>. C. Fc γ RIIIa V158 association with and dissociation from unmodified and afucosylated HLA-A2 mAbs. Dissociation rate (k_d) values are shown in inset.



Figure 4. Associations of serum derived HLA-A2 specific antibody fucosylation with Fc γ RIIIa binding and signaling. A. Spearman's correlation (R_S) between IgG1 fucosylation and Fc γ RIIIa dissociation rate (n=13). B. Fc γ RIIIa binding characterization in high (n=8), medium (n=8), low (n=8) fucose samples and negative controls (n=18). Serum samples were tested at a 1:500 serum dilution. Statistical analysis was performed using Ordinary one-way ANOVA adjusted for multiple comparisons using Tukey's test. Solid lines indicate group median. Data shown is representative of two technical replicates. C-D. Spearman's correlations between IgG1 fucosylation (n=24) (C), and Fc γ RIIIa signaling (n=31) (D) with Fc γ RIIIa binding (left) and IgG titer (right). Patients with AMR (red), patients without AMR (green), and patients with no AMR information (black) are indicated in color.



Figure 5. HLA-A2-specific IgG1 afucosylation is associated with AMR. A. Violin plot showing relative prevalence of fucose on HLA-A2-specific IgG1 in individuals with AMR (n=10) and without AMR (n=9). A Mann-Whitney U test was used to compare the two groups. **B.** Number of subjects in which HLA-A2-specific IgG1 comprise a DSA plotted by fucose content as tertiles (low, medium, high) and AMR status. Statistical significance defined by Fisher's exact test.



Graphical Abstract. Potential influence of HLA-A2-specific IgG1 afucosylation, FcγRIIIa binding and activation on ADCC and graft rejection. Illustration created with <u>https://BioRender.com</u>.